en Clinical Medicine Clinical Medicine مقاله پژوهشی Original Research Article <p style="text-align: justify;"><span style="font-size:16px;"><span style="font-family:Times New Roman;"><span style="color:#ffffff;"><strong><span style="background-color:#16a085;">Background and Objective:</span></strong></span> Dyskinesia is a debilitating complication of Parkinson&#39;s disease (PD), which appears due to some known risk factors. The effect of diabetes and high plasma glucose on the manifestation of dyskinesia has been evaluated in just a few previous reports. The current study aimed to assess the mentioned correlation.<br> <span style="color:#ffffff;"><strong><span style="background-color:#16a085;">Materials and Methods:</span></strong></span>&nbsp;In this case-control study, 88 patients with PD were enrolled and categorized into two equal groups of diabetic and non-diabetic patients. They were selected from the movement disorder clinic in Rasoul Akram Hospital, Tehran, Iran. Patients were evaluated regarding the presence of dyskinesia and its characteristics, besides the assessment of other clinical parameters.&nbsp;<br> <span style="color:#ffffff;"><strong><span style="background-color:#16a085;">Results:</span></strong></span>&nbsp;The prevalence of dyskinesia in diabetics, compared to non-diabetics, showed a higher rate (<em>P</em>=0.033). Baseline parameter equality was confirmed to exclude the confounding bias effect. Simultaneous involvement of upper and lower extremities (right after drug intake) was the most prevalent sign of dyskensia in diabetic patients with PD.<br> <span style="color:#ffffff;"><strong><span style="background-color:#16a085;">Conclusion:</span></strong></span>&nbsp;The comorbidity of PD and diabetes showed a higher prevalence of levodopa-induced dyskinesia (LID) in PD; this result was obtained based on homogeneity of the two groups in manners of age, disease, treatment duration and the dosage of levodopa.</span></span></p> Diabetes mellitus, Dyskinesia, Levodopa-induced dyskinesia, Parkinson’s disease 257 262 http://journal.zums.ac.ir/browse.php?a_code=A-10-5267-3&slc_lang=en&sid=1 Marzieh Mirzae m.mirzaei3991@gmail.com 5200319475328460064093 5200319475328460064093 No Dept. of Neurology, Rasoul Akram Hospital, Iran University of Medical Science, Tehran, Iran Mohammad Hossein Abbasi dr.m.h.abbasi95@gmail.com 5200319475328460064094 5200319475328460064094 No Dept. of Neurology, Rasoul Akram Hospital, Iran University of Medical Science, Tehran, Iran Gholam Ali Shahidi gshahidi@hotmail.com 5200319475328460064095 5200319475328460064095 No Dept. of Neurology, Rasoul Akram Hospital, Iran University of Medical Science, Tehran, Iran Qodsiye Hosseinifakhr gh.hosseinifakhr@gmail.com 5200319475328460064096 5200319475328460064096 No Dept. of Pharmacology and Toxicology, Faculty of Pharmacy, Tehran University of Medical Science, Tehran, Iran Farzad Sina Farzadsina48@yahoo.com 5200319475328460064097 5200319475328460064097 No Dept. of Neurology, Rasoul Akram Hospital, Iran University of Medical Science, Tehran, Iran Seyed Amirhassan Habibi Habibi.sah@iums.ac.ir 5200319475328460064098 5200319475328460064098 Yes Dept. of Neurology, Rasoul Akram Hospital, Iran University of Medical Science, Tehran, Iran